Inspirna
Inspirna (formerly Rgenix) is a privately-held cancer therapeutics company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. Using a mRNA-based target discovery platform developed by Inspirna's scientific co-founders at The Rockefeller University, the company is developing several first-in-class drug candidates to treat cancers of high unmet need. The company brings together distinguished scientific founders and a leadership team with a seasoned Board comprised of experienced drug developers. The company is funded by leading biotechnology investors, including Novo A/S, Sofinnova Partners, and Alexandria Venture Investments.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Active
Website
inspirna.com
Related News
Inspirna announces interim data from Phase 1b/2 study of Abequolixron (RGX-104) in relapsed or refractory lung cancer
Inspirna raises $50 million in Series D financing
Inspirna to present Phase 1b RGX-202-01 clinical trial data at the 2022 ESMO World Congress on Gastrointestinal Cancer
RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial
Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.